Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.75 as of 2026-09-15T22:21:04.065Z.
Consensus retrieved: 2026-09-13T23:55:50.738Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-15T22:21:04.065Z.
Quote observation: 2026-09-15T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0977b8a31e6ea7f9592b10cee9ae04021a425b0e7b389d5bba0cdf5189cd0787
Forward PE Ratio (18.75) = Dated Quote Price ($281.50) / Consensus Forward EPS ($15.01)
FORWARD PE RATIO
18.75
SECTOR MEDIAN · HEALTHCARE
19.08
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-1.73%
vs the sector median at left
Stryker Corporation
Market Cap
$107.92B
Forward PE Ratio
18.75
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Stryker Corporation (SYK) | $107.92B | 18.75 |
| McKesson Corporation (MCK)vs › | $105.32B | 20.16 |
| Sanofi (SNY)vs › | $101.81B | N/A |
| GSK plc (GSK)vs › | $100.20B | N/A |
| Medtronic plc (MDT)vs › | $120.00B | 15.69 |
| CVS Health Corp. (CVS)vs › | $120.56B | 11.81 |
| HCA Healthcare, Inc. (HCA)vs › | $91.76B | 14.38 |
| Elevance Health Inc. (ELV)vs › | $90.55B | 15.38 |
| Bristol-Myers Squibb Company (BMY)vs › | $130.18B | 9.20 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $130.62B | 27.45 |
Trailing P/E
29.2
reported TTM EPS
Forward P/E
18.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $15.01 implies +55.5% EPS growth vs the reported trailing $9.65.
At the dated quote price of $281.50, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $15.01 | $14.94 – $15.04 | 16 | 18.8x |
| 2027-12-31 | $16.75 | $16.11 – $17.13 | 16 | 16.8x |
| 2028-12-31 | $18.64 | $17.39 – $19.49 | 7 | 15.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
